Xeris Biopharma Holdings stock
XERSNASDAQXeris Biopharma Holdings, Inc., HealthcareISIN US98422E1038
55Score 55 out of 100, Neutral
Price and trend
77 / 100
Price history
+119% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 114% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 92).
The price is at its 52-week high. Largest decline in 8 years: 96% (September 2018 to January 2023).
Chart figures for advanced users
- SMA 50$10.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)92
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.29
- The lowest closing price of the last twelve months.
- Resistance$16.65
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Xeris Biopharma Holdings, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.04B, is number 101 of 289 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $387.9M (up 32.9%) and adjusted earnings per share of $0.01.
- MEQIRI Score 55 out of 100 (Neutral): rank 337 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $23.04, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 70.2% a year since 2020, Biotechnology median 19.4%.Growth 70
- High return on capitalReturn on invested capital 15% in fiscal 2025, Biotechnology median −24.3%.
Weaknesses
- DilutionShare count up 276% since 2020.Capital allocation 41
- High debtDebt 4.63 times equity (latest quarter), Biotechnology median 0.09.Stability 28
- Interest barely coveredOperating profit covers interest only 1 times.Stability 28
Its standout strengths are momentum and technical analysis, while fundamentals and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 56 to 55.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $16.46 and expensive above $38.40 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.5%. At 10.5% the fair value would be $19.04, at 8.5% it would be $28.79.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.4% on the twelve months before. Revenue has grown strongly since 2016, at around 86% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 9%, net 0%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 5 Nov 2026EPS reported $0.06 (expected $0.03)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.010.0%
- Revenue
- $387.9M0.0%
- Earnings per share
- $0.340.0%
- Revenue
- $480.03M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.2%Low end of the 2026 revenue guidance raised, range now $385 million to $390 million; SG&A to rise about $50 million instead of $45 million.
“Based on our strong first half performance and our conviction in the growth trajectory of this business, we are raising the bottom end of our full year 2026 total revenue guidance to $385 million to $390 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $3.72M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- McCulloch KevinSale
5 Nov 2026, See Remarks
- Shares
- 25,000
- Price
- $12.49
- Value
- $312,215
- Pieper StevenSale
2 Nov 2026, See Remarks
- Shares
- 5,000
- Price
- $10.23
- Value
- $51,174
- Hecht BethSale
2 Nov 2026, See Remarks
- Shares
- 25,000
- Price
- $10.23
- Value
- $255,828
Show 20 more
- McCulloch KevinSale
2 Nov 2026, See Remarks
- Shares
- 15,000
- Price
- $10.23
- Value
- $153,488
- Pieper StevenSale
1 Oct 2026, See Remarks
- Shares
- 5,000
- Price
- $9.41
- Value
- $47,037
- McCulloch KevinSale
1 Oct 2026, See Remarks
- Shares
- 15,000
- Price
- $9.41
- Value
- $141,120
- Hecht BethSale
1 Oct 2026, See Remarks
- Shares
- 16,666
- Price
- $9.41
- Value
- $156,792
- McCulloch KevinSale
28 Sept 2026, See Remarks
- Shares
- 25,000
- Price
- $10.00
- Value
- $250,000
- McCulloch KevinSale
1 Sept 2026, See Remarks
- Shares
- 15,000
- Price
- $8.49
- Value
- $127,308
- Hecht BethSale
1 Sept 2026, See Remarks
- Shares
- 16,666
- Price
- $8.49
- Value
- $141,434
- Pieper StevenSale
1 Sept 2026, See Remarks
- Shares
- 5,000
- Price
- $8.50
- Value
- $42,500
- Pieper StevenSale
12 Aug 2026, See Remarks
- Shares
- 5,000
- Price
- $8.50
- Value
- $42,500
- McCulloch KevinSale
3 Aug 2026, See Remarks
- Shares
- 15,000
- Price
- $8.02
- Value
- $120,240
- Hecht BethSale
3 Aug 2026, See Remarks
- Shares
- 16,666
- Price
- $8.01
- Value
- $133,553
- Pieper StevenSale
7 Jul 2026, See Remarks
- Shares
- 27,600
- Price
- $8.52
- Value
- $235,276
- Pieper StevenSale
6 Jul 2026, See Remarks
- Shares
- 17,400
- Price
- $8.50
- Value
- $147,900
- McCulloch KevinSale
1 Jul 2026, See Remarks
- Shares
- 90,000
- Price
- $8.03
- Value
- $722,511
- Hecht BethSale
1 Jul 2026, See Remarks
- Shares
- 16,666
- Price
- $8.03
- Value
- $133,860
- Halkuff DawnSale
4 Jun 2026, Board
- Shares
- 20,000
- Price
- $6.09
- Value
- $121,886
- Bormann-Kennedy Barbara-Jean AnneSale
4 Jun 2026, Board
- Shares
- 16,000
- Price
- $6.09
- Value
- $97,507
- Johnson JohnSale
4 Jun 2026, Board
- Shares
- 15,000
- Price
- $6.09
- Value
- $91,422
- Persky MarlaSale
3 Jun 2026, Board
- Shares
- 15,500
- Price
- $5.90
- Value
- $91,433
- Hecht BethSale
1 Jun 2026, See Remarks
- Shares
- 16,667
- Price
- $6.06
- Value
- $100,982
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Xeris Biopharma Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Dyne TherapeuticsDYN $3.19B34
- Telix PharmaceuticalsTLX $3.18B39
- Acadia PharmaceuticalsACAD $3.14B62
- IDEAYA BiosciencesIDYA $3.04B38
- Zai LabZLAB $2.94B50
- ADMA BiologicsADMA $2.94B71
- VericelVCEL $2.93B66
- XencorXNCR $2.86B47
ETFs that hold Xeris Biopharma Holdings
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 3.03% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.16% | 0.35% | €1.25B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.28B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.22B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.54B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.5B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €178.55M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.